trastuzumab,tucatinib
seagen
['tucatinib']
77% dcr with tucatinib + tras in refractory metastatic btc! sgntuc-19 trial! always check for her2 overexpression. #asco23
Medical Director, GI Oncology Program - AdventHealth Cancer Institute. Passionate about clinical research, education and pt-prov communication. #gicancer #meded